CRF2 Agonist for the Treatment of Worsening Heart Failure

Inclusion Criteria: * Signed written informed consent * Heart failure hospitalization (HFH) during previous 12 months * Prescribed an oral loop diuretic for at least 1 month preceding the index event * NT-proBNP ≥1,000 pg/mL or BNP ≥250 pg/mL * Requires treatment with i.v. diuretics for volume overload * At least 1 risk factor for diuretic resistance * Admitted to the hospital not more than 48 hours prior to randomization Exclusion Criteria: * Index event primarily triggered by an acute event (e.g. AMI, PE, arrhythmia) * Requirement for i.v. inotropic therapy or i.v. vasodilators, mechanical ventilation, high-flow oxygen therapy, or NIV * Requirement for, or planned use of LVADs, IABP, or any type of MCS * History of solid organ transplant or active on a transplant list * SBP \<100 mmHg * eGFR \< 20 mL/min/1.73 m2 * CABG, PCI, implantation of CRT, heart valve procedure or any cardiac surgery within 1 month prior to screening or planned during the study * Severe stenotic cardiac valvular disease * Severe chronic pulmonary disease requiring chronic steroid therapy or chronic oxygen therapy (\> 2 L/min) * Uncorrected severe hyperthyroidism or hypothyroidism * Severe restrictive, obstructive, or infiltrative cardiomyopathy * Body weight \< 70 kg * Use of any investigational drug(s) within 5 half-lives of screening * At high risk of death (defined as life expectancy ≤1 year) from causes other than heart failure or any disease that, in the opinion of the Investigator, will precl…